

Notification Under Executive Order 12372

This program is covered under E.O. 12372, "Intergovernmental Review of Federal Programs" and 45 CFR part 100, "Intergovernmental Review of Department of Health and Human Services Programs and Activities." However, since units of local governments are not funded in Fiscal Year 2003, the review and comment provisions of the Executive Order and part 100 do not apply for fiscal year 2003.

Paperwork Reduction Act

In accordance with the Paperwork Reduction Act of 1980 (Pub. L. 96-511), the application requirements contained in this notice have been approved by the Office of Management and Budget under control number 0348-0043.

TABLE I.—FY 2003 TENTATIVE ALLOCATIONS FOR ELECTION ASSISTANCE FOR INDIVIDUALS WITH DISABILITIES

State	FY 2003 tentative allotments
Alabama	185,341
Alaska	100,000
American Samoa	100,000
Arizona	209,686
Arkansas	109,029
California	1,371,756
Colorado	178,308
Connecticut	142,841
Delaware	100,000
District of Columbia	100,000
Florida	687,278
Georgia	335,237
Guam	100,000
Hawaii	100,000
Idaho	100,000
Illinois	511,102
Indiana	251,048
Iowa	122,161
Kansas	110,057
Kentucky	169,755
Louisiana	181,021
Maine	100,000
Maryland	219,527
Massachusetts	270,154
Michigan	409,083
Minnesota	202,382
Mississippi	115,296
Missouri	232,185
Montana	100,000
Nebraska	100,000
Nevada	100,000
New Hampshire	100,000
New Jersey	352,485
New Mexico	100,000
New York	795,936
North Carolina	339,029
North Dakota	100,000
Oregon	143,454
Ohio	471,600
Oklahoma	142,530
Pennsylvania	521,409
Puerto Rico	151,345

TABLE I.—FY 2003 TENTATIVE ALLOCATIONS FOR ELECTION ASSISTANCE FOR INDIVIDUALS WITH DISABILITIES—Continued

State	FY 2003 tentative allotments
Rhode Island	100,000
South Carolina	167,271
South Dakota	100,000
Tennessee	240,958
Texas	833,749
Utah	100,000
Vermont	100,000
Virgin Islands	100,000
Virginia	297,522
Washington	244,039
West Virginia	100,000
Wisconsin	185,426
Wyoming	100,000
Total	13,000,000

Dated: May 14, 2003.

Patricia A Morrissey,
*Commissioner, Administration on
 Developmental Disabilities*
 [FR Doc. 03-13394 Filed 5-28-03; 8:45 am]
BILLING CODE 4184-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Gastrointestinal Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Gastrointestinal Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on June 25 and 26, 2003, from 8:30 a.m. to 5 p.m.

Location: Marriott Washingtonian Center, The Ballrooms, 9751 Washingtonian Blvd., Gaithersburg, MD, 301-590-0044.

Contact Person: Thomas H. Perez, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301-827-6758, or e-mail: PerezT@cder.fda.gov, or FDA Advisory Committee Information

Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12538. Please call the Information Line for up-to-date information on this meeting.

Agenda: On June 25, 2003, the committee will discuss new drug application (NDA) 21-597, SEROSTIM (somatropin), Serono, Inc., for the treatment of short bowel syndrome in patients receiving specialized nutritional support. SEROSTIM therapy should be used in conjunction with optimal management of short bowel syndrome. On June 26, 2003, the committee will discuss NDA 21-525, PHOTOFRIN (porfimer sodium), Axcan Scandipharm, Inc. Photodynamic therapy with PHOTOFRIN is indicated for the ablation of high-grade dysplasia in Barrett's esophagus among patients who refuse esophagectomy and who are in overall good health.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by June 16, 2003. Oral presentations from the public will be scheduled between 1 p.m. and 2 p.m. on both days. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before June 16, 2003, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Thomas H. Perez at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: May 22, 2003.

Peter J. Pitts,
*Associate Commissioner for External
 Relations.*
 [FR Doc. 03-13318 Filed 5-28-03; 8:45 am]
BILLING CODE 4160-01-S